D. Fortuna, F. Margheri, S. Parker, F. Rossi
Applied Sciences, 16(1) 67, 2026
Words matter in science, particularly when they define technologies with distinct biological mechanisms. High-Intensity Laser Therapy (HILT) is often conflated with High-Power Laser Therapy or High-Level Laser Therapy (HPLT/HLLT), despite these terms referring to laser systems with fundamentally different physical properties and therapeutic effects. While many therapeutic lasers can elicit photochemical and photothermal effects, only devices delivering high-peak, short-duration pulses at very low duty cycles are able to generate acoustic pressure waves, which are characteristic of true HILT systems. These photoacoustic effects uniquely activate mechanotransduction pathways involved in cellular differentiation, extracellular matrix remodeling, and long-term tissue regeneration. This review highlights the widespread misclassification in the laser therapy literature, where devices lacking genuine photoacoustic capabilities are often incorrectly described as HILT. Such semantic ambiguity not only undermines biological specificity, but also inflates clinical claims, misleading practitioners, and obscures the comparative interpretation of clinical studies. Within the laser science community, it is widely recognized that average power alone is insufficient to characterize a therapeutic mechanism of laser therapies, as it does not provide insight into ability to generate pressure waves. To resolve these issues, we propose a mechanism-based classification that clearly distinguishes photochemical, photothermal, and photoacoustic effects. We further provide a quantitative comparison showing that systems delivering the same total energy produce peak parameters that differ by orders of magnitude depending on duty-cycle architecture, reinforcing the need for mechanism-based classification. We also advocate for greater rigor in reporting technical parameters such as peak power, pulse duration, and duty cycle. By ensuring proper terminology and transparent reporting, this framework will advance scientific rigor, facilitate accurate comparisons across studies, and improve the clinical application of regenerative medicine therapies.
L'accesso alla visualizzazione dei prodotti e al materiale informativo è riservato agli operatori del settore in ottemperanza alla legislazione vigente. ASA richiede di qualificarsi come operatore del settore per procedere con la navigazione.
Decreto Legislativo 24 febbraio 1997, n°46 Articolo 21
1. E' vietata la pubblicità verso il pubblico dei dispositivi che, secondo disposizioni adottate con decreto del Ministro della Sanità, possono essere venduti soltanto su prescrizione medica o essere impiegati eventualmente con l'assistenza di un medico o di altro professionista sanitario.
2. La pubblicità presso il pubblico dei dispositivi diversi da quelli di cui al comma 1 è soggetta ad autorizzazione del Ministero della Sanità. Sulle domande di autorizzazione esprime parere la Commissione di esperti prevista dall'articolo 6, comma 3, del decreto legislativo
30 dicembre 1992, n. 541, che a tal fine è integrata da un rappresentante del Dipartimento del Ministero della Sanità competente in materia di dispositivi medici e da uno del Ministero dell'Industria, del commercio e dell'artigianato.
Some of the contents of this website cannot be disclosed in the USA and its territories and possesions, for regulatory reasons. If you are a US resident, please click on the button here below and access ASA's distributor website for North America.